Latest News About Abattis Bioceuticals (OTCQB: ATTBF) (CSE: ATT)
ABATTIS ANNOUNCES RENEWAL OF HEALTH CANADA LICENCE
November 7, 2016
Abattis Bioceuticals Corp. | Vancouver, B.C.
Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQB: ATTBF) (CSE: ATT), announces the renewal of the Health Canada Licence for the Northern Vine Canada Inc. testing lab.
Health Canada has confirmed the renewal of the Langley, BC facility’s controlled substances testing licence. The Company has fulfilled Health Canada’s rigorous specifications, and successfully completed all thorough inspections. Accordingly, the lab has received its controlled substances licence renewal for the 2017 year.
The Company has worked hard to meet the requirements within Health Canada’s strictly regulated licensing environment. It is a testament to the professionalism of the team that has maintained the high standards of safety, quality and security in accordance with Health Canada’s regulations governing controlled substances testing facilities. This is an annual requirement and a big step toward Abattis entering the revenue stage for its shareholders.